DEA Cannabis Rescheduling Hearing Concludes July 15: What Happens Next

The Drug Enforcement Administration's landmark administrative hearing on whether to move adult-use marijuana from Schedule I to Schedule III of the Controlled Substances Act is scheduled to conclude no later than July 15, 2026. The proceeding, which opened on June 29, represents the furthest the federal government has advanced toward loosening its classification of cannabis since the plant was first placed in Schedule I in 1971.

But if you are expecting a dramatic gavel-drop verdict on July 15, temper your expectations. The end of the hearing is not the end of the process — it is closer to the halfway point of a long, procedurally dense rulemaking that could stretch months or, if history is any guide, years. Here's exactly what happens after the hearing closes, why the timeline is so uncertain, and what a move to Schedule III would actually change for the dispensaries and consumers who make up the legal market.

What just happened: a quick recap

The current hearing traces back to a proposed rule the Justice Department published in 2024 and revived under Executive Order 14370, which directed the DEA to complete cannabis rescheduling "in the most expeditious manner" possible. Earlier in 2026, the Justice Department took an interim step: it administratively placed FDA-approved marijuana products and state-licensed medical cannabis into Schedule III, while leaving the far larger adult-use market in Schedule I pending the outcome of this expedited hearing.

That split is the crux of the June 29–July 15 proceeding. The Administrative Law Judge (ALJ) is weighing whether the remaining, non-medical marijuana plant material also qualifies for Schedule III treatment. Designated Parties — a mix of industry operators, physicians, advocacy groups, and rescheduling opponents — presented testimony and evidence throughout the two-and-a-half-week window.

Notably, there are no live closing arguments. Once testimony wraps, the parties submit written post-hearing briefs summarizing their arguments and the evidentiary record. That is the first of several steps standing between today and any change at the retail counter.

The post-hearing timeline, step by step

Here is the sequence that follows the July 15 close, in order:

1. Post-hearing briefs

After the final witness, the Designated Parties file written briefs. These documents distill weeks of testimony into formal legal arguments about whether cannabis meets the three statutory criteria for Schedule III: a currently accepted medical use, a lower potential for abuse than Schedule I or II substances, and a risk of only moderate-to-low physical dependence.

2. The ALJ's recommended decision

After reviewing the evidence and the briefs, the Administrative Law Judge issues a recommended decision. Crucially, this is a recommendation, not a binding order. The ALJ cannot reschedule cannabis unilaterally; the judge advises the agency on what the record supports.

3. Review by the DEA Administrator

The ALJ's recommendation is forwarded to the DEA Administrator, who evaluates it alongside the full evidentiary record, the public comments submitted during the earlier rulemaking window, and the FDA's scientific and medical assessment — the eight-factor analysis that federal law requires before any scheduling change.

4. The Final Rule

If the Administrator concludes that rescheduling is warranted, the DEA publishes a Final Rule in the Federal Register. Only when that rule takes effect does adult-use marijuana's federal classification actually change. Until then, cannabis remains Schedule I at the federal level regardless of what any state has legalized.

5. Almost-certain litigation

Legal analysts widely expect that whatever the DEA decides, the losing side will challenge it in federal appeals court. Rescheduling opponents have signaled they will argue the process was flawed; some advocates, meanwhile, argue cannabis should be descheduled entirely rather than moved to Schedule III, and may litigate to push for that outcome. Either path adds time.

Why the timeline is so hard to pin down

The single most important thing to understand about rescheduling is that nobody can credibly promise a date. The President's executive order pushes for speed, but the administrative and judicial machinery has its own pace.

The cautionary precedent is the DEA's last full cannabis rescheduling hearing, in the 1980s. In that case:

• It took roughly two years after the hearing for the judge to issue a recommendation.
• It took another two years before the DEA published its final order.
• From the opening of hearings to the D.C. Circuit Court's final ruling, the entire process stretched nearly a decade — and it ended with cannabis staying in Schedule I.

No one expects a ten-year repeat this time; the political and scientific landscape has shifted enormously, and the executive branch is actively pushing the process forward rather than resisting it. But the 1980s precedent is a useful antidote to the assumption that July 15 means imminent change. A realistic read is months at minimum for the ALJ recommendation, with the Final Rule potentially landing in late 2026 or 2027 — and litigation capable of extending it further.

What Schedule III would actually change

If and when cannabis lands in Schedule III, the effects on the legal industry would be significant — but narrower than many headlines imply. Here's what would and wouldn't change.

The 280E tax penalty disappears

This is the single biggest financial consequence. Under IRS Code Section 280E, businesses that traffic in Schedule I or II controlled substances cannot deduct ordinary business expenses — rent, payroll, marketing — from their federal taxes. That has forced state-legal dispensaries to pay effective federal tax rates that routinely exceed 70%, crushing margins across the industry.

Schedule III drugs are not subject to 280E. A rescheduling would let operators deduct normal business expenses like any other company, freeing up cash that many analysts expect will flow into lower consumer prices, store expansion, hiring, and debt reduction. For an industry that has spent two years contracting under financial pressure, this is the headline benefit.

Medical research gets easier

Schedule I status makes cannabis research notoriously difficult, requiring special licenses and DEA-approved supply. Schedule III would streamline approvals and expand the pool of legal, standardized cannabis available to universities and pharmaceutical developers — accelerating the clinical evidence base that both regulators and consumers rely on.

What does NOT change

• Interstate commerce stays illegal. Rescheduling does not create a national marketplace. Cannabis grown in California still cannot legally cross into Nevada. State lines remain hard borders.
• State legality is unaffected. Rescheduling is a federal action. It does not legalize cannabis in prohibition states, and it does not override state licensing, testing, or retail rules.
• Dispensaries still operate under state law. Where you can legally buy, who can buy, and how products are tested continue to be governed by your state. The storefront experience does not change overnight.
• Banking is not automatically fixed. While Schedule III improves the picture, comprehensive banking access still largely depends on separate legislation like the SAFER Banking Act.

In short: Schedule III is a major financial and research reform for the legal industry, not a legalization event. The state-by-state patchwork consumers navigate today would remain intact.

What it means for consumers right now

For everyday shoppers, the practical takeaway is that nothing changes at the counter on July 15. Your state's dispensaries operate exactly as they did the day before. Prices won't drop that afternoon, menus won't expand overnight, and no new products become legal.

Over the longer term, if 280E relief materializes, the most likely consumer-facing effect is gradual price competition as operators pass along tax savings to defend market share against the illicit market. That is a story measured in quarters, not days.

The best thing consumers can do in the meantime is keep buying from licensed, compliant, state-legal retailers — the operators who stand to benefit from reform and who already meet testing and labeling standards. If you're not sure which stores near you are properly licensed, you can find a dispensary near you on Budpedia, where every listing is checked against state license records before it goes live.

The bottom line

The July 15 close of the DEA hearing is a genuine milestone — the first federal cannabis rescheduling proceeding to reach conclusion in a generation, and the one most likely to actually result in a change. But it is a milestone in a marathon, not a finish line. The real signposts to watch next are the post-hearing briefs, the ALJ's recommended decision, and ultimately a Final Rule in the Federal Register.

If that rule reschedules cannabis to Schedule III, the legal industry gets its most consequential financial reform in decades through the elimination of 280E — even as interstate commerce, state legality, and the day-to-day dispensary experience stay exactly where they are. For now, the smartest move is to watch the paperwork, ignore the hype cycle, and remember that federal reform reshapes the economics of the market long before it reshapes anything on the shelf.

Budpedia will update this article as the ALJ issues its recommendation and the DEA moves toward a Final Rule. Bookmark it for the latest on what Schedule III means for the dispensaries and prices you rely on.